Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1988 1
1997 1
2000 1
2011 1
2012 2
2013 4
2014 4
2015 3
2016 4
2017 5
2018 7
2019 5
2020 7
2021 3
2022 7
2023 9
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: kessler er. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Motzer RJ, et al. Among authors: kessler er. Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7. Lancet Oncol. 2022. PMID: 35688173 Free PMC article. Clinical Trial.
Management of Prostate Cancer in Older Adults.
Graham LS, Lin JK, Lage DE, Kessler ER, Parikh RB, Morgans AK. Graham LS, et al. Among authors: kessler er. Am Soc Clin Oncol Educ Book. 2023 May;43:e390396. doi: 10.1200/EDBK_390396. Am Soc Clin Oncol Educ Book. 2023. PMID: 37207299 Free article. Review.
What is behind the flare phenomenon?
Kessler ER. Kessler ER. BJU Int. 2016 Dec;118(6):845-846. doi: 10.1111/bju.13554. BJU Int. 2016. PMID: 27870361 No abstract available.
Reply by Authors.
Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; Collaborators. Margulis V, et al. Among authors: kessler er. J Urol. 2020 Apr;203(4):697-698. doi: 10.1097/JU.0000000000000644.02. Epub 2020 Jan 22. J Urol. 2020. PMID: 31967495 No abstract available.
Editorial: Bladder preservation options for bladder cancer.
Davis NB, Kilari D, Kessler ER, Smelser WW. Davis NB, et al. Among authors: kessler er. Front Oncol. 2024 Sep 26;14:1493854. doi: 10.3389/fonc.2024.1493854. eCollection 2024. Front Oncol. 2024. PMID: 39391248 Free PMC article. No abstract available.
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial.
Powles T, Burotto M, Escudier B, Apolo AB, Bourlon MT, Shah AY, Suárez C, Porta C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, George S, Scheffold C, Wang P, Fedorov V, Motzer RJ, Choueiri TK. Powles T, et al. Among authors: kessler er. ESMO Open. 2024 May;9(5):102994. doi: 10.1016/j.esmoop.2024.102994. Epub 2024 Apr 20. ESMO Open. 2024. PMID: 38642472 Free PMC article. Clinical Trial.
Cabozantinib use in renal cell carcinoma.
Neuwelt AJ, Mathur S, Johnson AT, Kessler ER, Bowles DW. Neuwelt AJ, et al. Among authors: kessler er. Drugs Today (Barc). 2017 May;53(5):299-307. doi: 10.1358/dot.2017.53.5.2623107. Drugs Today (Barc). 2017. PMID: 28650002 Review.
64 results